WST Stock Down -14% after 5-Day Loss Streak
West Pharmaceutical Services (WST) stock hit day 5 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -14% return. The company has lost about $2.6 Bil in value over the last 5 days, with its current market capitalization at about $18 Bil. The stock remains 26.8% below its value at the end of 2024. This compares with year-to-date returns of 7.8% for the S&P 500.
WST designs and manufactures injectable drug containment and delivery systems, operating in proprietary and contract-manufactured segments, distributing products via sales force and distribution network. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell WST.
Comparing WST Stock Returns With The S&P 500
The following table summarizes the return for WST stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | WST | S&P 500 |
|---|---|---|
| 1D | -4.0% | -0.4% |
| 5D (Current Streak) | -14.3% | -0.4% |
| 1M (21D) | 7.7% | 2.3% |
| 3M (63D) | 13.3% | 13.8% |
| YTD 2025 | -26.8% | 7.8% |
| 2024 | -6.8% | 23.3% |
| 2023 | 49.9% | 24.2% |
| 2022 | -49.7% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: WST Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 35 S&P constituents with 3 days or more of consecutive gains and 127 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 23 | 40 |
| 4D | 6 | 60 |
| 5D | 1 | 10 |
| 6D | 1 | 15 |
| 7D or more | 4 | 2 |
| Total >=3 D | 35 | 127 |
Key Financials for West Pharmaceutical Services (WST)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $2.9 Bil | $2.9 Bil |
| Operating Income | $707.4 Mil | $590.9 Mil |
| Net Income | $593.4 Mil | $492.7 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $748.8 Mil | $698.0 Mil |
| Operating Income | $169.8 Mil | $127.6 Mil |
| Net Income | $130.1 Mil | $89.8 Mil |
The losing streak WST stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.